<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021775</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 033</org_study_id>
    <secondary_id>10611</secondary_id>
    <nct_id>NCT00021775</nct_id>
  </id_info>
  <brief_title>HIV Prevention Preparedness Study in Russia, China, and India</brief_title>
  <official_title>HIV Prevention Preparedness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to set up a system for doing research on HIV prevention in&#xD;
      various parts of the world.&#xD;
&#xD;
      In order to plan large, long-term studies on the prevention of HIV in different areas of the&#xD;
      world, it is necessary to get certain information first. It is important to know about the&#xD;
      rate of HIV infection and how to get people to enroll for any future studies. This study will&#xD;
      be done at 4 study locations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to realistically plan for future Phase III studies on HIV prevention, information&#xD;
      must be obtained to characterize study population parameters at HTPN sites. Very different&#xD;
      study designs may be required depending on these parameters, such as the ability of HPTN&#xD;
      research centers to recruit study participants and the rate of HIV incidence observed in&#xD;
      study populations. This study will be conducted at 4 HPTN sites to establish the necessary&#xD;
      research knowledge and infrastructure.&#xD;
&#xD;
      This study enrolls participants from St. Petersburg, Russia; Xinjiang and Guangxi, China; and&#xD;
      Chennai, India who are at high risk for HIV infection due to sexual and/or drug use&#xD;
      behaviors. Participants who meet the screening criteria then complete an HIV risk assessment&#xD;
      interview, receive HIV pre-test and risk reduction counseling, and undergo phlebotomy for HIV&#xD;
      antibody testing. Participants who test positive are referred to available services and&#xD;
      studies. Those who test HIV-negative and meet eligibility criteria are enrolled and&#xD;
      maintained in follow-up over the next 12 months. Participants complete &quot;locator contacts&quot; at&#xD;
      Months 3 and 9 and have follow-up visits at Months 6 and 12 for similar tests as performed at&#xD;
      entry. In a substudy of this trial in China, participants will be interviewed about their&#xD;
      drug use, social networks, needs, and perceptions about HIV/AIDS. These results will be used&#xD;
      by HPTN to design more culturally sensitive and appropriate trials in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>2000</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Participants may be eligible for this study if they:&#xD;
&#xD;
          -  Are 16 (Saint Petersburg) or 18 (Xinjiang, Guangxi, and Chennai) years of age or&#xD;
             older.&#xD;
&#xD;
          -  Are HIV sero-negative.&#xD;
&#xD;
          -  Are available for 12 months of study participation.&#xD;
&#xD;
          -  Have written consent of parent or legal guardian if under age.&#xD;
&#xD;
          -  Are able and willing to provide information on where they can be located or contacted.&#xD;
&#xD;
          -  Meet specific risk-group requirements, for women at heterosexual risk, for men at&#xD;
             heterosexual risk, and for injection drug users.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Participants will not be eligible for this study if they:&#xD;
&#xD;
          -  Have any mental disorders that would cause a problem with the informed consent or&#xD;
             study participation.&#xD;
&#xD;
          -  Have any condition that, in the opinion of the doctor, would interfere with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ryder</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Guangxi Ctrs. for Disease Control &amp; Prevention and for HIV/AIDS Prevention &amp; Control CRS</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygar Autonomous Region Ctr. for Disease Control &amp; Prevention, HPTN Project Office</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Univ. Biomedical Ctr.</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1408</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>August 4, 2001</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risk Factors</keyword>
  <keyword>Incidence</keyword>
  <keyword>Patient Selection</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

